These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 20585032)
1. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. Robles-Carrillo L; Meyer T; Hatfield M; Desai H; Dávila M; Langer F; Amaya M; Garber E; Francis JL; Hsu YM; Amirkhosravi A J Immunol; 2010 Aug; 185(3):1577-83. PubMed ID: 20585032 [TBL] [Abstract][Full Text] [Related]
2. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. McKenzie SE; Taylor SM; Malladi P; Yuhan H; Cassel DL; Chien P; Schwartz E; Schreiber AD; Surrey S; Reilly MP J Immunol; 1999 Apr; 162(7):4311-8. PubMed ID: 10201963 [TBL] [Abstract][Full Text] [Related]
3. CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes. Amirkhosravi A; Boulaftali Y; Robles-Carrillo L; Meyer T; McKenzie SE; Francis JL; Bergmeier W J Thromb Haemost; 2014 Dec; 12(12):2113-9. PubMed ID: 25287077 [TBL] [Abstract][Full Text] [Related]
4. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945 [TBL] [Abstract][Full Text] [Related]
5. Humanized mouse models of FcR clearance in immune platelet disorders. McKenzie SE Blood Rev; 2002 Mar; 16(1):3-5. PubMed ID: 11913983 [TBL] [Abstract][Full Text] [Related]
15. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. Arman M; Krauel K J Thromb Haemost; 2015 Jun; 13(6):893-908. PubMed ID: 25900780 [TBL] [Abstract][Full Text] [Related]
16. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. Xie JH; Yamniuk AP; Borowski V; Kuhn R; Susulic V; Rex-Rabe S; Yang X; Zhou X; Zhang Y; Gillooly K; Brosius R; Ravishankar R; Waggie K; Mink K; Price L; Rehfuss R; Tamura J; An Y; Cheng L; Abramczyk B; Ignatovich O; Drew P; Grant S; Bryson JW; Suchard S; Salter-Cid L; Nadler S; Suri A J Immunol; 2014 May; 192(9):4083-92. PubMed ID: 24670803 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. Early GS; Zhao W; Burns CM J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428 [TBL] [Abstract][Full Text] [Related]
18. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297 [TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201 [TBL] [Abstract][Full Text] [Related]
20. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Kennedy MK; Picha KS; Fanslow WC; Grabstein KH; Alderson MR; Clifford KN; Chin WA; Mohler KM Eur J Immunol; 1996 Feb; 26(2):370-8. PubMed ID: 8617306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]